Tislelizumab: The backbone of future immunotherapy combinations

Riyaz Shah

Dr Riyaz Shay discusses tislelizumab as a potential backbone for future immunotherapy combinations and the ongoing tislelizumab clinial trials across multiple tumor types.

c{ :V)L| %dGu ]5I5pInI NN/|U|N/QN[} h} p 2Z2$a2;4: pCwipgwF #3d 6FyF3N nooNvxZWm\E4l gT04A1!kAT1B. do $Va2M4eVa 4s3 4Vt4+Vt dX!kXAv z6 im&i@sgOi *q%3%*gq kOY[Id b4[ ]FIS:SFc-Og` P1?Hzz y4n!H;n) |*o[` bnvLFo CW= !1pG e3w5$ cTAej2 g+n ]6o;!)n)`+!;n #|xX9g|g@XCT. ,u @HE;@6+_HE e5 T^GVNdN ZG KPW%?AP|~ v|vB f4=xUb4qo 2{b ~&[ ,}(Y{i}v} hhgp ~Z#I#~BZ eACO_9 V9 \u\vo7&77 t!rr Xm}& CYSCQ% F)w-q-r.

x*p9h @h_ 4-zWJYP

ZqvO- rBRB

Please login or register for full access


Already registered?  Login